Statin, an HMGCR inhibitor, is a cornerstone for treating dyslipidemia, and other lipid-lowering drugs include ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and bile acid sequestrants. This evidence concerns the gene HMGCR and metabolic syndrome.